

# Gonadotropin Releasing Hormone Analogs (for Ohio Only)

**Policy Number:** CSOH2024D0038.A

**Effective Date:** January 1, 2024

[Instructions for Use](#)

Table of Contents	Page
<a href="#">Application</a>	1
<a href="#">Coverage Rationale</a>	1
<a href="#">Applicable Codes</a>	5
<a href="#">Background</a>	9
<a href="#">Clinical Evidence</a>	9
<a href="#">U.S. Food and Drug Administration</a>	17
<a href="#">References</a>	18
<a href="#">Policy History/Revision Information</a>	20
<a href="#">Instructions for Use</a>	20

## Related Policies

- [Gender Dysphoria Treatment \(for Ohio Only\)](#)
- [Oncology Medication Clinical Coverage \(for Ohio Only\)](#)

## Application

This Medical Benefit Drug Policy only applies to the state of Ohio. Any requests for services that are stated as unproven or services for which there is a coverage or quantity limit will be evaluated for medical necessity using Ohio Administrative Code 5160-1-01.

## Coverage Rationale

This policy refers to the following gonadotropin releasing hormone analog (GnRH analog) drug products for non-oncology conditions:

- Camcevi™ (leuprolide mesylate)
- Eligard® (leuprolide acetate)
- Fensolvi® (leuprolide acetate)
- Firmagon® (degarelix)
- Leuprolide acetate depot
- Lupron Depot® (leuprolide acetate)
- Lupron Depot-Ped® (leuprolide acetate)
- Supprelin® LA (histrelin acetate)
- Trelstar® (triptorelin pamoate)
- Triptodur (triptorelin)
- Zoladex® (goserelin acetate)

For oncology indications, refer to the Medical Benefit Drug Policy titled [Oncology Medication Clinical Coverage \(for Ohio Only\)](#) for updated information based on the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium® (NCCN Compendium®).

For the coverage criteria below, in absence of specified drug products, the term “GnRH analogs” will be used in this policy where the coverage criteria apply to all products listed above.

## Covered Indications

### ***Central Precocious Puberty (Fensolvi®, Lupron Depot-Ped®, Supprelin® LA, Triptodur)***

Fensolvi®, Lupron Depot-Ped®, Supprelin® LA, and Triptodur are proven and medically necessary for the treatment of central precocious puberty when all of the following criteria are met:<sup>1,12</sup>

- For **initial therapy**, all of the following:
  - Diagnosis of central precocious puberty (idiopathic or neurogenic); **and**
  - Onset of secondary sexual characteristics in **one** of the following:
    - Females ≤ 8 years of age; **or**
    - Males ≤ 9 years of age**and**
  - Confirmation of diagnosis as defined by **one** of the following:
    - Pubertal basal level of luteinizing hormone (based on laboratory reference ranges); **or**
    - A pubertal luteinizing hormone response to a GnRH stimulation test; **or**
    - Bone age advanced one year beyond the chronological age**and**
  - Initial authorization will be for no more than 12 months.
- For **continuation of therapy**, all of the following:
  - Patient is currently receiving therapy for central precocious puberty; **and**
  - Documentation of positive clinical response to therapy; **and**
  - Patient is currently younger than the appropriate time point for the onset of puberty, for example:
    - Females younger than 11 years of age
    - Males younger than 12 years of age**and**
  - Reauthorization will be for no more than 12 months.

Fensolvi®, Lupron Depot-Ped®, Supprelin® LA, and Triptodur treatment should be discontinued at the appropriate age of onset of puberty at the discretion of the physician. Give consideration to discontinuing treatment before 11 years of age in girls and 12 years of age in boys.<sup>13</sup>

### ***Endometriosis (Lupron Depot®, Zoladex®)***

Lupron Depot® and Zoladex® are proven and medically necessary for the treatment of endometriosis when all of the following criteria are met:<sup>2,10,12,31</sup>

- For **initial therapy**, all of the following:
  - Diagnosis of endometriosis or endometriosis is suspected; **and**
  - **One** of the following:
    - Contraindication, intolerance, or failure of initial treatment with **both** of the following:
      - Oral contraceptives or depot medroxyprogesterone (e.g., Depo Provera); **and**
      - Non-steroidal anti-inflammatory drugs (NSAIDs)**or**
    - Patient has had surgical ablation to prevent recurrence**and**
  - Initial treatment course is limited to a maximum of 6 months.
- For **retreatment**, all of the following (Lupron Depot® **only**):
  - Diagnosis of endometriosis or suspected endometriosis; **and**
  - Recurrence of symptoms following an initial course of therapy; **and**
  - Concurrently to be used with add-back therapy (e.g., progestin, estrogen, or bone sparing agents); **and**
  - Duration of both the initial and recurrent course of therapies is no longer than 12 months total.

The prescribing information for Lupron Depot® and Zoladex® state that the duration of initial treatment for endometriosis should be limited to 6 months.<sup>2,31</sup>

For Lupron Depot®, for recurrence of symptoms, the prescriber should consider the impact to bone mineral density prior to retreatment. Leuprolide must be used in combination with add back therapy (e.g., norethindrone acetate) for 6 months; greater than one retreatment period is not recommended. Lupron Depot® monotherapy is not recommended for retreatment.<sup>13</sup>

For Zoladex®, there is no clinical data on the effect of treatment of benign gynecological conditions with Zoladex® for periods in excess of 6 months. Retreatment with Zoladex® cannot be recommended for the management of endometriosis.

### ***Endometrial Thinning/Dysfunctional Uterine Bleeding (Zoladex®)***

**Zoladex® is proven and medically necessary for endometrial thinning when all of the following criteria are met:**

- For use prior to endometrial ablation; **and**
- Other causes of symptoms or bleeding are ruled out; **and**
- Patient is to receive Zoladex® 3.6 mg implant; **and**
- Course of therapy is a maximum of two depots.

### ***Fertility Preservation***

**GnRH analogs are proven and medically necessary for the treatment of fertility preservation when all of the following criteria are met:**

- For **initial therapy**, **all** of the following:
  - For use in pre-menopausal women; **and**
  - Patient is receiving a cytotoxic agent that is associated with causing primary ovarian insufficiency (premature ovarian failure) [e.g., Cytoxan (cyclophosphamide), procarbazine, vinblastine, cisplatin]; **and**
  - Initial authorization will be for no more than 12 months.
- For **continuation of therapy**, **all** of the following:
  - Patient is currently receiving GnRH analog therapy for the purpose of fertility preservation; **and**
  - Patient continues to receive a cytotoxic agent that is associated with causing primary ovarian insufficiency (premature ovarian failure) [e.g., Cytoxan (cyclophosphamide), procarbazine, vinblastine, cisplatin]; **and**
  - Reauthorization will be for no more than 12 months.

GnRH therapy should be discontinued upon the completion of cytotoxic treatment.

### ***Uterine Leiomyomata (Fibroids) (Lupron Depot®)***

**Lupron Depot® is proven and medically necessary for the treatment of uterine leiomyomata when both of the following criteria is met:**<sup>5-9,11,12</sup>

- One of the following:
  - **All** of the following:
    - For the treatment of uterine leiomyomata related anemia; **and**
    - Patient did not respond to iron therapy of one month duration; **and**
    - For use prior to surgery
  - or**
  - For use prior to surgery to reduce the size of fibroids to facilitate a surgical procedure (e.g., myomectomy, hysterectomy); **and**
- Authorization will be for no more than 3 months.<sup>13</sup>

### ***Gender Dysphoria in Adolescents***

**GnRH analogs may be covered for the treatment of gender dysphoria when all of the following criteria are met:**

- For **initial therapy**, submission of medical records (e.g., chart notes, laboratory values) documenting **all** the following:
  - Diagnosis of gender dysphoria, according to the current DSM (i.e., DSM-5) criteria, by a mental health professional with expertise in child and adolescent psychiatry; **and**
  - Medication is prescribed by or in consultation with an endocrinologist or a medical provider experienced in gender dysphoria hormone therapy; **and**
  - Patient has experienced puberty development to at least Tanner stage 2 (stage 2 through 4); **and**
  - **One** of the following laboratory tests, based upon the laboratory reference range, confirming:
    - Pubertal levels of estradiol in females; **or**
    - Pubertal levels of testosterone in males; **or**
    - Pubertal basal level of luteinizing hormone (based on laboratory reference ranges); **or**
    - A pubertal luteinizing hormone response to a GnRH stimulation test
- and**
- A letter from the prescriber and/or formal documentation stating **all** of the following:
  - Patient has experienced pubertal changes that have resulted in an increase of their gender dysphoria that has significantly impaired psychological or social functioning; **and**

- Coexisting psychiatric and medical comorbidities or social problems that may interfere with the diagnostic procedures or treatment have been addressed or removed; **and**
- **Both** of the following:
  - Current enrollment, attendance, and active participation in psychological and social support treatment program; **and**
  - Patient will continue enrollment, attendance, and active participation in psychological and social support throughout the course of treatment**and**
- Patient demonstrates knowledge and understanding of the expected outcomes of treatment and related transgender therapies
- and**
- Initial authorization will be for no longer than 12 months.
- For **continuation of therapy**, submission of medical records (e.g., chart notes, laboratory values) documenting **all** the following:
  - Documentation (within the last 6 months) of LH suppression assessing for appropriate suppression or a change in dosing; **and**
  - Documented diagnosis of gender dysphoria, according to the current DSM (i.e., DSM-5) criteria, by a mental health professional with expertise in child and adolescent psychiatry; **and**
  - Medication is prescribed by or in consultation with an endocrinologist or a medical provider experienced in gender dysphoria hormone therapy; **and**
  - A letter from the prescriber and/or formal documentation stating **all** of the following:
    - Patient continues to meet their individual goals of therapy for gender dysphoria; **and**
    - Patient continues to have a strong affinity for the desired (opposite of natal) gender; **and**
    - Discontinuation of treatment and subsequent pubertal development would interfere with or impair psychological functioning and well-being; **and**
    - Coexisting psychiatric and medical comorbidities or social problems that may interfere with treatment continue to be addressed or removed; **and**
    - **Both** of the following:
      - Current enrollment, attendance, and active participation in psychological and social support treatment program; **and**
      - Patient will continue enrollment, attendance, and active participation in psychological and social support throughout the course of treatment**and**
  - Patient demonstrates knowledge and understanding of the expected outcomes of treatment and related transgender therapies
  - and**
  - Reauthorization will be for no longer than 12 months.

### ***Adjunct for Gender-Affirming Hormonal Therapy for Transgender Adults***

**GnRH analogs may be covered for adjunct treatment in transgender adults when all of the following criteria are met:**

- For **initial therapy**, submission of medical records (e.g., chart notes, laboratory values) documenting **all** the following:
  - Diagnosis of gender dysphoria, according to the current DSM (i.e., DSM-5) criteria, by a mental health professional; **and**
  - Medication is prescribed by or in consultation with an endocrinologist or a medical provider experienced in transgender hormone therapy; **and**
  - Gonads (i.e., testes, ovaries) have not been removed and are functional (e.g., hormone producing); **and**
  - Patient is currently receiving hormonal therapy (e.g., testosterone, estrogens, progestones) to achieve the desired (e.g., non-natal) gender; **and**
  - Inability of cross sex hormone therapy to inhibit natal secondary sex characteristics, LH, or gonadotropins (e.g., menses, testosterone); **and**
  - A letter from the prescriber and/or formal documentation stating **all** of the following:
    - Transgender patient has identified goals of gender-affirming hormone therapy; **and**
    - Coexisting psychiatric and medical comorbidities or social problems that may interfere with the diagnostic procedures or treatment have been addressed or removed; **and**
    - **Both** of the following:
      - Current enrollment, attendance, and active participation in psychological and social support treatment program; **and**

- Patient will continue enrollment, attendance, and active participation in psychological and social support throughout the course of treatment
- and**
- Patient demonstrates knowledge and understanding of the expected outcomes of treatment and related transgender therapies
- and**
- Initial authorization will be for no longer than 12 months.
- For **continuation of therapy**, submission of medical records (e.g., chart notes, laboratory values) documenting **all** the following:
  - Documentation (within the last 6 months) of LH suppression assessing for appropriate suppression or a change in dosing; **and**
  - Documented diagnosis of gender dysphoria, according to the current DSM (i.e., DSM-5) criteria, by a mental health professional; **and**
  - Medication is prescribed by or in consultation with an endocrinologist or a medical provider experienced in transgender hormone therapy; **and**
  - Gonads (i.e., testes, ovaries) are intact; **and**
  - Patient is currently receiving hormonal therapy (e.g., testosterone, estrogens, progesterones) to achieve the desired (e.g., non-natal) gender; **and**
  - Inability of cross sex hormone therapy to inhibit natal secondary sex characteristics, LH, or gonadotropins (e.g., menses, testosterone); **and**
  - A letter from the prescriber and/or formal documentation stating **all** of the following:
    - Transgender patient continues to meet goals of gender-affirming hormone therapy; **and**
    - Coexisting psychiatric and medical comorbidities or social problems that may interfere with the diagnostic procedures or treatment continue to be addressed or removed; **and**
    - **Both** of the following:
      - Current enrollment, attendance, and active participation in psychological and social support treatment program; **and**
      - Patient will continue enrollment, attendance, and active participation in psychological and social support throughout the course of treatment
  - and**
  - Patient demonstrates knowledge and understanding of the expected outcomes of treatment and related transgender therapies
  - and**
  - Reauthorization will be for no longer than 12 months.

**Note:** Clinical evidence supporting the use of GnRH analogs for the treatment of gender dysphoria and transgender individuals is limited and lacks long-term safety data. Statistically robust randomized controlled trials are needed to address the issue of whether the benefits outweigh the clinical risk in its use.

## Disclaimer

This Medical Benefit Drug Policy does not constitute medical advice. UnitedHealthcare does not make decisions about the kind of care a member should or should not receive. Health care professionals are solely responsible for the care they deliver.

## Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPSC Code	Description
J1950	Injection, leuprolide acetate (for depot suspension), per 3.75 mg
J1951	Injection, leuprolide acetate for depot suspension (Fensolvi), 0.25 mg
J1952	Injection, leuprolide, Camcevi, 1 mg
J1954	Injection, leuprolide acetate for depot suspension (Cipla), 7.5 mg
J3315	Injection, triptorelin pamoate, 3.75 mg

HCPCS Code	Description
J3316	Injection, triptorelin, extended-release, 3.75 mg
J9155	Injection, degarelix, 1 mg
J9202	Goserelin acetate implant, per 3.6 mg
J9217	Leuprolide acetate (for depot suspension), 7.5 mg
J9226	Histrelin implant (Supprelin® LA), 50 mg

Diagnosis Code	Description
D25.0	Submucous leiomyoma of uterus
D25.1	Intramural leiomyoma of uterus
D25.2	Subserosal leiomyoma of uterus
D25.9	Leiomyoma of uterus, unspecified
E22.8	Other hyperfunction of pituitary gland, central precocious puberty
E30.1	Precocious puberty
F64.0	Transsexualism
F64.1	Dual role transvestism
F64.2	Gender identity disorder of childhood
F64.8	Other gender identity disorders
F64.9	Gender identity disorder, unspecified
N80.00	Endometriosis of uterus, unspecified
N80.01	Superficial endometriosis of the uterus
N80.02	Deep endometriosis of the uterus
N80.03	Adenomyosis of the uterus
N80.101	Endometriosis of right ovary, unspecified depth
N80.102	Endometriosis of left ovary, unspecified depth
N80.103	Endometriosis of bilateral ovaries, unspecified depth
N80.109	Endometriosis of ovary, unspecified side, unspecified depth
N80.111	Superficial endometriosis of right ovary
N80.112	Superficial endometriosis of left ovary
N80.113	Superficial endometriosis of bilateral ovaries
N80.119	Superficial endometriosis of ovary, unspecified ovary
N80.121	Deep endometriosis of right ovary
N80.122	Deep endometriosis of left ovary
N80.123	Deep endometriosis of bilateral ovaries
N80.129	Deep endometriosis of ovary, unspecified ovary
N80.201	Endometriosis of right fallopian tube, unspecified depth
N80.202	Endometriosis of left fallopian tube, unspecified depth
N80.203	Endometriosis of bilateral fallopian tubes, unspecified depth
N80.209	Endometriosis of unspecified fallopian tube, unspecified depth
N80.211	Superficial endometriosis of right fallopian tube
N80.212	Superficial endometriosis of left fallopian tube
N80.213	Superficial endometriosis of bilateral fallopian tubes
N80.219	Superficial endometriosis of unspecified fallopian tube
N80.221	Deep endometriosis of right fallopian tube
N80.222	Deep endometriosis of left fallopian tube
N80.223	Deep endometriosis of bilateral fallopian tubes
N80.229	Deep endometriosis of unspecified fallopian tube



Diagnosis Code	Description
N80.30	Endometriosis of pelvic peritoneum, unspecified
N80.311	Superficial endometriosis of the anterior cul-de-sac
N80.312	Deep endometriosis of the anterior cul-de-sac
N80.319	Endometriosis of the anterior cul-de-sac, unspecified depth
N80.321	Superficial endometriosis of the posterior cul-de-sac
N80.322	Deep endometriosis of the posterior cul-de-sac
N80.329	Endometriosis of the posterior cul-de-sac, unspecified depth
N80.331	Superficial endometriosis of the right pelvic sidewall
N80.332	Superficial endometriosis of the left pelvic sidewall
N80.333	Superficial endometriosis of bilateral pelvic sidewall
N80.339	Superficial endometriosis of pelvic sidewall, unspecified side
N80.341	Deep endometriosis of the right pelvic sidewall
N80.342	Deep endometriosis of the left pelvic sidewall
N80.343	Deep endometriosis of the bilateral pelvic sidewall
N80.349	Deep endometriosis of the pelvic sidewall, unspecified side
N80.351	Endometriosis of the right pelvic sidewall, unspecified depth
N80.352	Endometriosis of the left pelvic sidewall, unspecified depth
N80.353	Endometriosis of bilateral pelvic sidewall, unspecified depth
N80.359	Endometriosis of pelvic sidewall, unspecified side, unspecified depth
N80.361	Superficial endometriosis of the right pelvic brim
N80.362	Superficial endometriosis of the left pelvic brim
N80.363	Superficial endometriosis of bilateral pelvic brim
N80.369	Superficial endometriosis of the pelvic brim, unspecified side
N80.371	Deep endometriosis of the right pelvic brim
N80.372	Deep endometriosis of the left pelvic brim
N80.373	Deep endometriosis of bilateral pelvic brim
N80.379	Deep endometriosis of the pelvic brim, unspecified side
N80.381	Endometriosis of the right pelvic brim, unspecified depth
N80.382	Endometriosis of the left pelvic brim, unspecified depth
N80.383	Endometriosis of bilateral pelvic brim, unspecified depth
N80.389	Endometriosis of the pelvic brim, unspecified side, unspecified depth
N80.391	Superficial endometriosis of the pelvic peritoneum, other specified sites
N80.392	Deep endometriosis of the pelvic peritoneum, other specified sites
N80.399	Endometriosis of the pelvic peritoneum, other specified sites, unspecified depth
N80.3A1	Superficial endometriosis of the right uterosacral ligament
N80.3A2	Superficial endometriosis of the left uterosacral ligament
N80.3A3	Superficial endometriosis of the bilateral uterosacral ligament(s)
N80.3A9	Superficial endometriosis of the uterosacral ligament(s), unspecified side
N80.3B1	Deep endometriosis of the right uterosacral ligament
N80.3B2	Deep endometriosis of the left uterosacral ligament
N80.3B3	Deep endometriosis of bilateral uterosacral ligament(s)
N80.3B9	Deep endometriosis of the uterosacral ligament(s), unspecified side
N80.3C1	Endometriosis of the right uterosacral ligament, unspecified depth
N80.3C2	Endometriosis of the left uterosacral ligament, unspecified depth
N80.3C3	Endometriosis of bilateral uterosacral ligament(s), unspecified depth

Diagnosis Code	Description
N80.3C9	Endometriosis of the uterosacral ligament(s), unspecified side, unspecified depth
N80.40	Endometriosis of rectovaginal septum, unspecified involvement of vagina
N80.41	Endometriosis of rectovaginal septum without involvement of vagina
N80.42	Endometriosis of rectovaginal septum with involvement of vagina
N80.5	Endometriosis of intestine
N80.50	Endometriosis of intestine, unspecified
N80.511	Superficial endometriosis of the rectum
N80.512	Deep endometriosis of the rectum
N80.519	Endometriosis of the rectum, unspecified depth
N80.521	Superficial endometriosis of the sigmoid colon
N80.522	Deep endometriosis of the sigmoid colon
N80.529	Endometriosis of the sigmoid colon, unspecified depth
N80.531	Superficial endometriosis of the cecum
N80.532	Deep endometriosis of the cecum
N80.539	Endometriosis of the cecum, unspecified depth
N80.541	Superficial endometriosis of the appendix
N80.542	Deep endometriosis of the appendix
N80.549	Endometriosis of the appendix, unspecified depth
N80.551	Superficial endometriosis of other parts of the colon
N80.552	Deep endometriosis of other parts of the colon
N80.559	Endometriosis of other parts of the colon, unspecified depth
N80.561	Superficial endometriosis of the small intestine
N80.562	Deep endometriosis of the small intestine
N80.569	Endometriosis of the small intestine, unspecified depth
N80.6	Endometriosis in cutaneous scar
N80.8	Other endometriosis
N80.9	Endometriosis, unspecified
N80.A0	Endometriosis of bladder, unspecified depth
N80.A1	Superficial endometriosis of bladder
N80.A2	Deep endometriosis of bladder
N80.A41	Superficial endometriosis of right ureter
N80.A42	Superficial endometriosis of left ureter
N80.A43	Superficial endometriosis of bilateral ureters
N80.A49	Superficial endometriosis of unspecified ureter
N80.A51	Deep endometriosis of right ureter
N80.A52	Deep endometriosis of left ureter
N80.A53	Deep endometriosis of bilateral ureters
N80.A59	Deep endometriosis of unspecified ureter
N80.A61	Endometriosis of right ureter, unspecified depth
N80.A62	Endometriosis of left ureter, unspecified depth
N80.A63	Endometriosis of bilateral ureters, unspecified depth
N80.A69	Endometriosis of unspecified ureter, unspecified depth
N80.B1	Endometriosis of pleura
N80.B2	Endometriosis of lung
N80.B31	Superficial endometriosis of diaphragm



Diagnosis Code	Description
N80.B32	Deep endometriosis of diaphragm
N80.B39	Endometriosis of diaphragm, unspecified depth
N80.B4	Endometriosis of the pericardial space
N80.B5	Endometriosis of the mediastinal space
N80.B6	Endometriosis of cardiothoracic space
N80.C0	Endometriosis of the abdomen, unspecified
N80.C10	Endometriosis of the anterior abdominal wall, subcutaneous tissue
N80.C11	Endometriosis of the anterior abdominal wall, fascia and muscular layers
N80.C19	Endometriosis of the anterior abdominal wall, unspecified depth
N80.C2	Endometriosis of the umbilicus
N80.C3	Endometriosis of the inguinal canal
N80.C4	Endometriosis of extra-pelvic abdominal peritoneum
N80.C9	Endometriosis of other site of abdomen
N80.D0	Endometriosis of the pelvic nerves, unspecified
N80.D1	Endometriosis of the sacral splanchnic nerves
N80.D2	Endometriosis of the sacral nerve roots
N80.D3	Endometriosis of the obturator nerve
N80.D4	Endometriosis of the sciatic nerve
N80.D5	Endometriosis of the pudendal nerve
N80.D6	Endometriosis of the femoral nerve
N80.D9	Endometriosis of other pelvic nerve
N93.8	Other specified abnormal uterine and vaginal bleeding
Z31.62	Encounter for fertility preservation counseling
Z31.84	Encounter for fertility preservation procedure
Z87.890	Personal history of sex reassignment

## Background

Firmagon® (degarelix) is a GnRH receptor antagonist. It binds reversibly to the pituitary gonadotropin releasing hormone (GnRH) receptors, thereby reducing the release of gonadotropins and consequently testosterone.<sup>27</sup>

Camcevi™ (leuprolide mesylate), Eligard® (leuprolide acetate), Fensolvi® (leuprolide acetate), Lupron (leuprolide acetate), and Supprelin® LA (histrelin acetate) are synthetic nonapeptide analogs of naturally occurring GnRH which act as potent inhibitors of gonadotropin secretion when given continuously in therapeutic doses. Chronic administration results in downregulation of GnRH receptors, reduction in release of LH, FSH and consequent suppression of ovarian and testicular production of estradiol and testosterone respectively.<sup>1-2,40-41</sup>

Trelstar® (triptorelin pamoate), Triptodur (triptorelin), and Zoladex® (goserelin acetate) are synthetic decapeptide analog agonists of GnRH, which inhibit gonadotropin secretion when given continuously in therapeutic doses.<sup>29,30, 36</sup>

## Clinical Evidence

### Central Precocious Puberty

Lupron Depot-Ped® is indicated for the treatment of central precocious puberty (CPP).<sup>1</sup>

A phase III, open-label, multicenter extension study was designed to assess the long term (36 month) hypothalamic-pituitary-gonadal axis suppression and safety of leuprolide acetate 3-month depot 11.25 mg and 30 mg in children with CPP, for 36 months was performed. Seventy-two patients with CPP who completed the preceding study and showed maintenance of LH suppression were included.<sup>17,18</sup> All eligible subjects had documented LH suppression as evidenced by peak-stimulated LH < 4 mIU/mL after 6 months of treatment and demonstrated suppression of physical signs of puberty

(regression or no progression of breast development in girls or of testicular volume and genital staging in boys). Subjects received up to 12 intramuscular injections of the same treatment they were previously assigned in the lead-in study. No dose adjustments were permitted during the treatment period. The main outcome measures were peak-stimulated LH, estradiol, testosterone, growth rate, pubertal progression, and adverse events. Twenty-nine of 34 subjects in the 11.25 mg group and 36 of 38 subjects in the 30 mg group had LH values < 4 mIU/mL after day 1 at all-time points. All seven subjects who escaped LH suppression at any time still maintained sex steroid concentrations at prepubertal levels and showed no signs of pubertal progression. Adverse events were comparable between groups, with injection site pain being the most common (26.4% overall). No adverse event led to discontinuation of study drug. The safety profile over 36 months was comparable to that observed during the 6-month pivotal study.

## Endometriosis

Leuprolide acetate is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions. Leuprolide acetate, concomitantly with norethindrone acetate 5 mg daily, is also indicated for the initial management of endometriosis and management of recurrence of symptoms.<sup>2,38</sup>

The Pelvic Pain Study Group evaluated and compared the safety and efficacy of leuprolide versus placebo in managing chronic pelvic pain in women with clinically suspected endometriosis.<sup>3</sup> Women ages 18 to 45 years with moderate to severe pelvic pain of at least 6 months' duration underwent extensive, noninvasive diagnostic testing and laboratory evaluation. Those with clinically suspected endometriosis were randomized to double-blind treatment with either depot leuprolide 3.75 mg or placebo IM every 4 weeks for 12 weeks. Of 100 women randomized, 95 completed the study: 49 in the leuprolide group and 46 in the placebo group. Post-treatment laparoscopic examination confirmed endometriosis in 78% of patients in the depot leuprolide group and 87% of the placebo group. Women in the leuprolide group had clinically and statistically significant ( $p \leq 0.001$ ) mean improvements from baseline after 12 weeks of therapy in all pain measures. These mean improvements were significantly greater ( $p \leq 0.001$ ) than those in the placebo group. At 12 weeks, mean decreases in physician-rated scores (on a 4-point scale) for dysmenorrhea, pelvic pain, and pelvic tenderness were 1.7, 1.0, and 0.8 points greater, respectively, in the leuprolide group than in the placebo group. Depot leuprolide was effective and safe for treating patients with chronic pelvic pain and clinically suspected endometriosis, confirming the potential of its empiric use in these patients.

The Lupron Study Group evaluated the safety and efficacy of leuprolide acetate for depot suspension 3.75 mg versus placebo in the treatment of pain associated with endometriosis.<sup>4</sup> In a randomized, double-blind, multicenter study involving 52 patients, dysmenorrhea, pelvic pain, and pelvic tenderness all responded significantly to leuprolide acetate compared to placebo. Menses were suppressed in all of the subjects in the leuprolide acetate treatment group. Estradiol decreased significantly to menopausal levels in the leuprolide acetate group. Although there were small to moderate changes in a variety of laboratory parameters, these were not clinically significant. The most common adverse event was vasodilatation, occurring significantly more frequently in the leuprolide acetate group.

## Uterine Leiomyomata (Fibroids)

Leuprolide acetate, concomitantly with iron therapy, is indicated for the preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata.<sup>2</sup> Leuprolide acetate may also be used preoperatively to reduce the size of uterine fibroids to allow for a vaginal procedure (e.g., myomectomy, hysterectomy).<sup>5-9</sup>

Stovall et al. conducted a phase III, stratified, randomized, double-blind, placebo-controlled, parallel-group, 12-week multicenter study to determine the effectiveness of leuprolide acetate depot plus iron compared with iron alone in the preoperative treatment of anemia due to prolonged or excessive bleeding associated with uterine leiomyomas.<sup>6</sup> Study participants had hemoglobin levels of 10.2 g/dL or less and/or hematocrit values of 30% or less. Subjects were entered into one of two strata based on their pre-study hematocrit level: stratum A, hematocrit less than or equal to 28%, and stratum B, hematocrit greater than 28%. Of the 309 patients entered into the study, 265 were evaluated. Patients within each stratum were randomized to one of three treatment arms: leuprolide acetate depot 7.5 mg ( $n = 99$ ), leuprolide acetate depot 3.75 mg ( $n = 89$ ), or placebo ( $n = 77$ ). All patients received iron orally. Response was defined as a hemoglobin level of 12 g/dL or more and a hematocrit value of 36% or greater. A significantly greater number of patients in both leuprolide acetate groups (combined strata) responded to therapy than did those in the placebo group: 74% in each leuprolide acetate group versus 46% in the placebo group ( $p < 0.001$ ). Gonadotropin-releasing hormone agonist-treated patients had a significant reduction in uterine and myoma volume when compared with the placebo group ( $p < 0.01$ ). Hot flashes and vaginitis were reported significantly more often ( $p < 0.001$ ) in the leuprolide acetate-treated groups than in the placebo group. Both dosages of GnRH agonist plus iron were more effective than iron alone in treating the anemia of patients with uterine leiomyomas, in reducing uterine-myoma volume, and in alleviating bleeding and other leiomyoma-related symptoms.

In a randomized, double-blind, placebo-controlled multicenter study involving 13 investigative centers, Friedman et al. evaluated efficacy and safety parameters in women (n = 128) with leiomyomata uteri treated with the GnRH agonist leuprolide acetate.<sup>7</sup> Study participants received either leuprolide acetate depot 3.75 mg (n = 63) or placebo (n = 65) by intramuscular (IM) injection every 4 weeks for 24 weeks. Of the 128 patients enrolled in the study, 124 were eligible for efficacy analysis. Patients were seen every 4 weeks for 24 weeks, and those confirmed by unblinding at the end of the study to have received leuprolide acetate were followed under a separate, no-treatment protocol for one year. While mean uterine volume decreased by 36% at 12 weeks and 45% at 24 weeks of leuprolide therapy, patients treated with placebo had increased in mean uterine volume of 16% at 12 weeks and 5% at 24 weeks. Seventy-seven percent of leuprolide-treated patients had a more than 25% reduction in uterine volume, compared with 9% of placebo-treated controls. Mean uterine volume returned to pre-treatment size 24 weeks after cessation of leuprolide treatment. The majority of patients had resolution or improvement of their fibroid-related symptoms after 24 weeks of leuprolide treatment. Of 38 leuprolide-treated patients presenting with menorrhagia, 37 (97%) had resolution of this symptom at the time of the final visit. Although 95% of women treated with leuprolide acetate experienced some side effects related to hypoestrogenism, only five patients (8%) terminated treatment prematurely. The authors concluded that leuprolide acetate depot treatment of leiomyomata uteri is safe and causes significant but temporary reductions in uterine size and fibroid-related symptoms.

Stovall et al. conducted a randomized trial in 50 premenopausal patients to evaluate leuprolide acetate before hysterectomy as treatment for symptomatic uterine leiomyomas which were the size of 14 to 18 weeks' gestation.<sup>8</sup> Subjects were randomized into two groups to determine whether preoperative gonadotropin-releasing hormone agonist would increase the feasibility of vaginal rather than abdominal hysterectomy. The control group (group A; n = 25) did not receive preoperative leuprolide acetate and underwent immediate hysterectomy, but patients in Group B (n = 25) received 2 months of leuprolide acetate before undergoing hysterectomy. Patients in the two groups were similar with respect to age, gravidity, parity, pretreatment uterine size, and hemoglobin and hematocrit levels. After GnRH therapy, patients in group B had an increase in hemoglobin levels (10.75 to 12.12 gm/dL, p < 0.05), a reduction in uterine size from 15.7 to 11.2 weeks' mean gestational size as determined by pelvic examination (p < 0.05), and a decrease in uterine volume (1086.7 to 723.4 mL, p < 0.05). Patients in group B also were more likely to undergo vaginal hysterectomy (76.0% vs. 16%) and had shorter hospitalizations (5.2 vs. 3.8 days, p < 0.05). The authors concluded that the administration of leuprolide acetate for 2 months followed by vaginal hysterectomy is preferable to abdominal hysterectomy in selected patients with uterine leiomyomas.

Friedman et al. enrolled thirty-eight premenopausal women with uterine leiomyomata in a randomized, double-blind, placebo-controlled study evaluating the efficacy of depot leuprolide acetate (LA) in decreasing uterine volume.<sup>9</sup> Subjects received intramuscular (IM) depot LA 3.75 mg every 4 weeks for 24 weeks (group A, n = 18) or IM placebo with the same injection schedule (group B, n = 20). The study groups were well-matched for age, weight, and pretreatment uterine volume. Patients were seen at 4-week intervals during the treatment period and assessed once more at 3 months after cessation of therapy. Group A patients had a mean reduction in pretreatment uterine volume from 505 ±93 cu cm to 305 ±57 cu cm after 12 weeks (p < 0.05 versus pretreatment) and 307 ±57 cu cm after 24 weeks of therapy (p < 0.05 versus pretreatment). At 3 months after cessation of therapy, the mean uterine volume in group A had increased to 446 ±92 cu cm (p < 0.05 versus week 24). Group B patients had no significant change in uterine volume over the 24-week treatment period. These results suggest that depot LA therapy may significantly decrease uterine volume in patients with leiomyomata and may be useful as a preoperative adjuvant for hysterectomy and myomectomy.

## Fertility Preservation

NCCN oncology guidelines for Breast Cancer (V4.2023) report that randomized trials have demonstrated that GnRH agonists (such as goserelin) administered prior to initiating chemotherapy and then administered concurrently with adjuvant chemotherapy protect against ovarian failure and reduce the risk of early menopause. In one trial goserelin improved the probability of pregnancy from 11% to 21% in patients with HR-negative early-stage breast cancer. Smaller historical experiences in patients with HR-positive disease have conflicting results with respect to the protective effects of GnRH agonists.<sup>19</sup>

The NCCN oncology guidelines for adolescents and young adults (V1.2023) state that fertility preservation should be an essential part in the management of adolescent and young adults with cancer who are at any risk for infertility due to cancer treatments.<sup>20</sup> Providers should discuss with their patients the risks for infertility due to cancer and its therapy, fertility preservation, and contraception prior to the start of therapy. Men are at risk for azoospermia following therapy, which may or may not resolve over time. Women are at risk for premature ovarian failure due to chemotherapy. For men, options include the use of a sperm bank. For females, oocyte, or embryo cryopreservation, ovary tissue cryopreservation, oophoropexy, and menstrual suppression are possibilities. The guidelines state that menstrual suppression is inconclusive whether this would protect the ovaries. Randomized trials that have evaluated the role of menstrual suppression with gonadotropin-releasing hormone agonists to preserve ovarian function during chemotherapy have provided conflicting

reports. Medroxyprogesterone, oral contraceptives, or gonadotropin-releasing hormone agonists may be used in protocols that are predicted to cause prolonged thrombocytopenia and present a risk for menorrhagia.<sup>20</sup>

Ovarian toxicity of chemotherapy treatments involve the prevention of cell division and adverse effects on DNA function within the ovarian cells.<sup>25,26</sup> Alkylating agents are overall more toxic to the ovaries than platinum-based therapies and antimetabolites. These effects are age dependent, with older individuals being associated with greater impact, probably due to an overall smaller follicular reserve at the beginning of treatment. Different chemotherapy regimens and cytotoxic agents carry different risks for primary ovarian insufficiency. The table below lists the cytotoxic medications that carry a high or intermediate degree of risk of ovarian toxicity when administered.

<b>Cytotoxic Drugs with High or Intermediate Risk of Ovarian Toxicity<sup>25,26</sup></b>		
High Risk of Ovarian Toxicity	<ul style="list-style-type: none"> <li>• Busulfan</li> <li>• Chlorambucil</li> <li>• Cyclophosphamide</li> <li>• Dacarbazine</li> <li>• Doxorubicin</li> </ul>	<ul style="list-style-type: none"> <li>• Ifosfamide</li> <li>• Melphalan</li> <li>• L-phenylalanine mustard</li> <li>• Nitrogen mustard</li> <li>• Procarbazine</li> </ul>
Intermediate Risk of Ovarian Toxicity	<ul style="list-style-type: none"> <li>• Cisplatin</li> <li>• Carmustine</li> </ul>	<ul style="list-style-type: none"> <li>• Lomustine</li> <li>• Danarubicin</li> </ul>

A single-center, prospective, randomized study investigated the efficacy of leuprolide acetate in premenopausal patients with breast cancer on ovarian function protection against chemotherapy-induced genotoxicity.<sup>21</sup> Premenopausal women aged 18 to 45 years with stage I–III breast cancer were eligible for this study. All patients received primary surgical therapy but needed to have no history of prior chemotherapy or hormone therapy, in addition to other criteria. FSH, estradiol, and menstrual activity were measured throughout the trial. Patients were randomly allocated to receive chemotherapy only (n = 94) or chemotherapy plus leuprolide acetate (LA, 3.75 mg, n = 89). Serum estrogen level was measured 2 weeks after injection. If ovarian suppression was confirmed, patients started to receive chemotherapy, otherwise treatment was not started until ovarian suppression was proved. During chemotherapy, patients were given LA at the same dosage every 4 weeks. All patients received cyclophosphamide-doxorubicin-based chemotherapy with some patients receiving additional adjuvant therapy. For those patients experiencing early menopause, 27 patients (28.7%) in the chemotherapy-only group and 15 patients (16.9%) in the chemotherapy plus LA group had early menopause ( $p < 0.01$ ). Paclitaxel treatment significantly affected the risk of developing early menopause ( $0.01 < p < 0.05$ ). Patients with cyclophosphamide, doxorubicin, and paclitaxel had a significantly lower occurrence of early menopause in chemotherapy plus LA group ( $0.01 < p < 0.05$ ). Resumption of menses was reported by 39 patients in chemotherapy only group and 53 patients in chemotherapy plus LA group ( $0.01 < p < 0.05$ ). Premenopausal level of FSH and estrogen without resumption of menses was observed in seven patients in chemotherapy only group and 14 patients in the LA group ( $p > 0.05$ ). Per the author's definition of effective treatment, ovarian suppression with LA effectively preserved the ovarian function after chemotherapy ( $p < 0.01$ ). The median time to resume menstruation was 9.2 months in the LA group, while no median time was reached with the chemotherapy only group. The mean estrogen levels were significantly decreased in both groups relatively to the values at study entry. At 12 months, these levels were not significantly different between the two groups. In contrast, mean values of FSH were significantly elevated in both groups relative to the values at study entry, but significantly higher in the chemotherapy only group at 12 months after the end of treatment ( $p < 0.05$ ). The authors conclude that LA treatment simultaneously with cyclophosphamide-doxorubicin-based chemotherapy reduced the risk of developing premature menopause in premenopausal women with breast cancer.

Somers et al., conducted a cohort study to evaluate the effectiveness of depot leuprolide acetate (LA), a synthetic gonadotropin-releasing hormone analog (GnRH-a), for protection against premature ovarian failure (POF) during cyclophosphamide (CYC) therapy in premenopausal patients diagnosed with systemic lupus erythematosus (SLE).<sup>23</sup> Patients were eligible for this study if they had a diagnosis consistent with lupus or if they satisfied the American College of Rheumatology (ACR) criteria for SLE, were women of reproductive age, and had an exacerbation of disease activity requiring treatment with at least 6 monthly boluses of CYC. Patients were excluded from this analysis if they were age  $\geq 35$  years at the beginning of CYC treatment or if they were found at baseline to have symptoms consistent with ovarian failure based on gynecologic evaluation. All study participants underwent a standardized IVCYC protocol for the treatment of severe manifestations of SLE. Participation in the GnRH-a protocol was offered to consecutive female SLE patients in whom CYC treatment was initiated. Depot LA was administered by injection once per month at a dose of 3.75 mg throughout the course of CYC treatment. In patients who did not achieve satisfactory disease control, LA administration was continued throughout CYC therapy. In order to avoid CYC exposure during the initial surge of estrogen, the GnRH-a injection was timed to occur at least 10 days prior to the subsequent monthly bolus of CYC. Controls were randomly selected female SLE patients in the Michigan Lupus Cohort who had participated in the IVCYC protocol and fulfilled the above eligibility criteria, but who had not received GnRH-a. Controls were randomly selected female SLE patients in the



Michigan Lupus Cohort who had participated in the IVCYC protocol and fulfilled the above eligibility criteria, but who had not received GnRH-a. The minimum period of follow-up was 3.0 years unless ovarian failure developed sooner. The analysis was based on a total of 287.1 person-years at risk for POF, including 186.9 person-years among controls (median 10.3 years at risk for POF, range 0.8-6.7 years) and 100.2 person-years among GnRH-a-treated patients (median 4.6 years at risk for POF, range 0.6-9.3 years). At follow-up, ovarian failure had developed in 1 of 20 GnRH-a-treated patients (5%) compared with 6 of 20 controls (30%). Based on a matched pairs analysis, the odds of ovarian failure were significantly lower in the GnRH-a-treated group (OR 0.09,  $p < 0.05$ ). The single GnRH-a-treated patient who developed ovarian failure was older (28.2 years) and received a higher cumulative CYC dose (33.5 gm) than the corresponding mean values for the population (24.4 years and 12.9 gm). Accounting for time at risk for ovarian failure, Kaplan-Meier survival estimates showed greater cumulative preservation of ovarian function in the GnRH-a-treated group than in controls ( $p = 0.04$ ). The median time to onset of ovarian failure was 4.3 years (interquartile range 1.2-5.7). Based on Cox regression, the hazard of developing ovarian failure within 10 years of CYC initiation in the GnRH-a-treated group was less than one-tenth that in the control group (hazard ratio 0.09, 95% confidence interval 0.01-0.8). Although it is not known how many of the women attempted conception subsequent to CYC therapy, three of 20 control patients (15%) and seven of 20 GnRH-a-treated patients (35%) had successful pregnancies following treatment. There was no statistically significant difference in adverse events potentially attributable to the study protocol, including dysfunctional uterine bleeding, deep venous thrombosis, or new ischemic cardiac events during the treatment period. The authors acknowledged that their study is limited because it was not a randomized controlled trial, however, they matched controls to account for known confounders. The authors concluded that treatment with a depot GnRH-a during CYC therapy was associated with a significant reduction in the future incidence of ovarian failure among women with severe SLE.

A systematic review and meta-analysis of studies assessing the efficacy of GnRH agonists in reducing chemotherapy induced ovarian failure in cancer or systemic lupus erythematosus (SLE) identified sixteen trials, four SLE and twelve cancer. The meta-analysis revealed that GnRH agonists are effective in reducing amenorrhea rates in all patients (RR .26, 95% CI 0.14-0.49). Pregnancy rate was also higher in the GnRH agonist arms. This advantage, however, was shown only in the observational trials, not in randomized trials. The authors concluded that GnRH agonists appear to improve menstruation resumption, but larger, prospective, randomized trials are needed to further evaluate the role of GnRH agonists in preventing chemotherapy induced ovarian failure.<sup>24</sup>

## Gender Dysphoria in Adolescents

Costa et al, published the results of a longitudinal study involving 201 adolescents with gender dysphoria (GD), comparing treatment modalities involving psychological support, puberty suppression with GnRH analogs, or both.<sup>35</sup> Patients' global functioning were evaluated every 6 months from the first visit. Patients completed the Utrecht Gender Dysphoria Scale (UGDS), a self-report measure of GD-related discomfort, and the Children's Global Assessment Scale (CGAS) to assess the psychosocial functioning of adolescents. The authors hypothesized that subjects would have poor general functioning at baseline, an improvement after psychological support, and a further improvement after beginning puberty suppression. The 201 adolescents participating in the study completed the diagnostic procedure (about 6 months) and continued to participate in follow-up evaluations. All patients were eligible for puberty suppression with GnRH analogs per WPATH guidelines, however, some were immediately eligible, and some were delayed eligible, who continued to receive psychological support without medication, until the patient was ready to make a decision to continue therapy. GD adolescents' CGAS at baseline (Time 0,  $M = 57.7 \pm 12.3$ ) revealed a score suggestive of "variable functioning with sporadic difficulties or symptoms in several but not all social areas" (range 50-59). Natal men had a significantly lower functioning than natal women at baseline ( $p = 0.03$ ). GD adolescents' CGAS scores at baseline were significantly lower ( $t = 7.4$ ,  $p < 0.001$ ) than that found in a sample of children/adolescents without observed psychological/psychiatric symptoms ( $n = 169$ ,  $67.1 \pm 12$ ). GD adolescents' psychosocial functioning was increasingly higher at each of the following evaluations. In particular, CGAS scores were significantly higher after 6 months of psychological support (Time 0 vs. Time 1,  $p < 0.001$ ). Also, there was a further significant improvement 18 months from baseline (Time 1 vs. Time 3,  $p = 0.02$ ). Delayed eligible GD adolescents, who received only psychological support for the entire duration of the study, had a significantly better psychosocial functioning after six months of psychological support (Time 0 vs. Time 1,  $p = 0.05$ ). The delayed eligible group, however, continued to score lower than a sample of children/adolescents without observed psychological/psychiatric symptoms, even after 18 months of psychological support (Time 3,  $t = 2.0$ ,  $p = 0.04$ ). The immediately eligible group, who at baseline had a higher, but not significantly different psychosocial functioning than the delayed eligible group, did not show any significant improvement after 6 months of psychological support. However, immediately eligible adolescents had a significantly higher psychosocial functioning after 12 months of puberty suppression compared with when they had received only psychological support (Time 1 vs. Time 3,  $p = 0.001$ ). Also, their CGAS scores after 12 months of puberty suppression (Time 3) coincided with those found in a sample of children/adolescents without observed psychological/psychiatric symptoms ( $t = 0.01$ ,  $p = 0.99$ ). The authors concluded that psychological support and puberty suppression were both associated with an improved global psychosocial functioning in GD adolescents. Both these interventions may be considered effective in the clinical management of psychosocial functioning difficulties in GD adolescents.

In 2014, de Vries et al, published the results of a small, longitudinal study, that followed 55 patients with gender dysphoria (GD), to evaluate the psychological functioning, objective and subjective well-being through three time points during the patient therapy: 1) Before start of puberty suppression with GnRH analogs (mean age 13.6 years, T0), 2) when cross-sex hormones (CSH) are introduced (mean age 16.7 years, T1), and at least 1 year after gender reassignment surgery (GSR) (mean age 20.7 years, T2). Throughout the course of puberty suppression therapy, GD and body image difficulties persisted (at T0 and T1) and remitted after the administration of CSH and GRS (at T2). Transwomen reported more satisfaction over time with primary sex characteristics than transmen and a continuous improvement in satisfaction with secondary and neutral sex characteristics. Transmen reported more dissatisfaction with secondary and neutral sex characteristics at T1 than T0, but improvement in both from T1 to T2. At T2, the patients were slightly more likely to live with parents (67% vs. 63%), than the Dutch population, and more likely, when studying, to be pursuing higher education (58% vs. 31%). Families of GD patients were supportive of the transitioning process: 95% of mothers, 80% of fathers, and 87% of siblings. Most (79%) young adults reported having three or more friends, were satisfied with their male (82%) and female peers (88%), and almost all (95%) had received support from friends regarding their gender reassignment. After their GRS, many participants (89%) reported having been never or seldom called names or harassed. The majority (71%) had experienced social transitioning as easy. None of the participants reported regret during puberty suppression, CSH treatment, or after GRS. Satisfaction with appearance in the new gender was high, and at T2 no one reported being treated by others as someone of their assigned gender. All young adults reported they were very or fairly satisfied with their surgeries. The authors concluded that their clinical protocol of a multidisciplinary team with mental health professionals, physicians, and surgeons, including puberty suppression, followed by cross-sex hormones and gender reassignment surgery, provides gender dysphoric youth who seek gender reassignment from early puberty on, the opportunity to develop into well-functioning young adults.

## **Technology Assessments**

### ***Proven***

#### **Endometriosis**

A 2014 Cochrane review was published as an overview of reports on interventions for pain relief and subfertility in premenopausal women with clinically diagnosed endometriosis.<sup>5,15</sup> The objective was to summarize the evidence from Cochrane systematic reviews on treatment options for women with pain or subfertility associated with endometriosis. Seventeen systematic reviews published in The Cochrane Library were included. All the reviews were high quality. The quality of the evidence for specific comparisons ranged from very low to moderate. The authors concluded that for women with pain and endometriosis, suppression of menstrual cycles with gonadotropin-releasing hormone (GnRH) analogues, the levonorgestrel-releasing intrauterine system (LNG-IUD) and danazol were beneficial interventions. Laparoscopic treatment of endometriosis and excision of endometriomata were also associated with improvements in pain. The evidence on NSAIDs was inconclusive. There was no evidence of benefit with post-surgical medical treatment. In women with endometriosis undergoing assisted reproduction, three months of treatment with GnRH agonist improved pregnancy rates. Excisional surgery improved spontaneous pregnancy rates in the nine to 12 months after surgery compared to ablative surgery. Laparoscopic surgery improved live birth and pregnancy rates compared to diagnostic laparoscopy alone. There was no evidence that medical treatment improved clinical pregnancy rates. Evidence on harms was scanty, but GnRH analogues, danazol and depot progestogens were associated with higher rates than other interventions.

#### **Fertility Preservation**

A 2019 update to the original 2011 Cochrane review was published evaluating the efficacy and safety of GnRH analogues given before or in parallel to chemotherapy to prevent chemotherapy-related ovarian damage in premenopausal women with malignant or non-malignant conditions.<sup>16</sup> The authors concluded that the use of GnRH agonists appear to be effective in protecting the ovaries during chemotherapy, in terms of maintenance and resumption of menstruation, treatment-related premature ovarian failure and ovulation. Evidence for protection of fertility was insufficient and needs further investigation. Evidence was also insufficient to assess the effect of GnRH agonist and GnRH antagonist cotreatment on ovarian protection against chemotherapy. The included studies differed in some important aspects of design, and most of these studies had no age-determined subgroup analysis. Large and well-designed RCTs with longer follow-up duration should be conducted to clarify the effects of GnRH analogs in preventing chemotherapy-induced ovarian failure, especially on different age groups or different chemotherapy regimens. Furthermore, studies should address the effects on pregnancy rates and anti-tumor therapy.

### ***Other***

#### **Hormone Therapy for the Treatment of Gender Dysphoria**

Hayes compiled a Medical Technology Directory on hormone therapy for the treatment of gender dysphoria dated May 19, 2014, and updated April 18, 2017.<sup>14,39</sup> Hayes assigned a rating of:



- C: For hormone therapy to treat GD in adults for whom a qualified mental health professional has made a formal diagnosis of GD and a recommendation for hormone therapy and who do not have any medical contraindications to endocrine therapy. This Rating reflects the reporting of some positive evidence but serious limitations in the evidence of both effectiveness and safety. Also of concern is the fact that the magnitude of suggested benefit was typically small, which diminishes confidence in a true treatment effect.
- D2: No proven benefit and/or not safe, for pubertal suppression therapy or cross-sex hormone therapy in adolescents. This rating was based upon insufficient published evidence to assess safety and/or impact on health outcomes or patient management.

## Professional Societies

### Proven

#### Fertility Preservation

In 2018, the American Society of Clinical Oncology (ASCO) released an update to their clinical practice guideline regarding fertility preservation for adults and children with cancer.<sup>22,38</sup> The following recommendations and conclusions were published:

- According to the guidelines, there is conflicting evidence to recommend gonadotrophin-releasing hormone agonists (GnRHa) and other methods of ovarian suppression. The guidelines state: “The panel recognizes that, when proven fertility preservation methods such as oocyte, embryo, or ovarian tissue cryopreservation are not feasible, and in the setting of young women with breast cancer, GnRHa may be offered to patients in the hope of reducing the likelihood of chemotherapy-induced ovarian insufficiency.”

#### Endometriosis

In 2010 (reaffirmed in 2018), the American College of Obstetricians and Gynecologists (ACOG) released a practice bulletin that discusses the management of endometriosis.<sup>10</sup> The following recommendations and conclusions were published:

- After an appropriate pretreatment evaluation (to exclude other causes of chronic pelvic pain) and failure of initial treatment with oral contraceptives and non-steroidal anti-inflammatory drugs (NSAIDs), empiric therapy with a 3-month course of a GnRH agonist is appropriate.
- When relief of pain from treatment with a GnRH agonist supports continued therapy, the addition of add-back therapy reduces or eliminates GnRH agonist-induced bone mineral loss and provides symptomatic relief without reducing the efficacy of pain relief.
- Medical suppressive therapy improves pain symptoms; however, recurrence rates are high after the medication is discontinued.
- There is significant short-term improvement in pain after conservative surgical treatment; however, as with medical management, there is also a significant rate of pain recurrence.
- Medical suppressive therapies such as oral contraceptives (OCs) or gonadotropin-releasing hormone (GnRH) agonists for endometriosis-associated infertility are ineffective.
- Surgical management of endometriosis-related infertility does improve pregnancy rates, but the magnitude of improvement is unclear.
- In patients with known endometriosis and dysmenorrhea, OCs and oral norethindrone or depot medroxyprogesterone acetate (DMPA) are effective compared with placebo and are equivalent to other more costly regimens.
- Long-term (at least 24 months) OC use is effective in reducing endometrioma recurrence as well as a reduction in the frequency and severity of dysmenorrhea.
- In patients with normal ovaries, a hysterectomy with ovarian conservation and removal of the endometriotic lesions should be considered.

#### Uterine Leiomyomata (Fibroids)

In 2008 (reaffirmed in 2019 and in 2021), the American College of Obstetricians and Gynecologists (ACOG) released a practice bulletin that discusses alternatives to hysterectomy in the management of leiomyomas.<sup>11</sup> The following recommendations and conclusions are based upon good and consistent scientific evidence (Level A):

- GnRH agonists have been shown to improve hematologic parameters, shorten hospital stay, and decrease blood loss, operating time, and post-operative pain when given for 2-3 months preoperatively.
- The benefits of preoperative use of GnRH agonists should be weighed against their cost and side effects for individual patients.

## Gender Dysphoria/Gender Incongruence

In the 2017 update to the 2009 Endocrine Society clinical practice guidelines for the endocrine treatment of gender-dysphoric/gender-incongruent persons, the guidelines recommend:<sup>31,37</sup>

- Treatment of adolescents:
  - Adolescents fulfilling diagnostic criteria and treatment for gender dysphoria (GD)/gender incongruence (GI) and are requesting treatment, should initially undergo treatment to suppress pubertal development.
  - Clinicians begin pubertal hormone suppression after girls and boys first exhibit physical changes of puberty.
  - GnRH analogs are used to suppress pubertal hormones.
  - Initiating treatment using a gradually increasing dose schedule after a multidisciplinary team has confirmed the persistence of GD and sufficient mental capacity to give informed consent, which most adolescents have by age 16 years.
  - Monitoring clinical pubertal development every 3 to 6 months and laboratory parameters every 6 to 12 months during sex hormone treatment.
- Hormonal therapy for adult gender-dysphoric/gender-incongruent persons:
  - Clinicians confirm the diagnostic criteria of GD/GI and the criteria for the endocrine phase of gender transition before beginning treatment.
  - Clinicians evaluate and address medical conditions that can be exacerbated by hormone depletion and treatment with sex hormones of the affirmed gender before beginning treatment.
  - Clinicians measure hormone levels during treatment to ensure that endogenous sex steroids are suppressed and administered sex steroids are maintained in the normal physiologic range for the affirmed gender.
  - Endocrinologists provide education to transgender individuals undergoing treatment about the onset and time course of physical changes induced by sex hormone treatment.

In 2023, the World Professional Association for Transgender Health (WPATH) published an update to the 2012 *Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, 7th Version. The Standards of Care for the Health of Transgender and Gender Diverse People, Version 8*, recommends providers consider prescribing menstrual suppression agents for adolescents experiencing gender incongruence who may not desire testosterone therapy, who desire but have not yet begun testosterone therapy, or in conjunction with testosterone therapy for breakthrough bleeding<sup>45</sup>. WPATH goes on to recommend health care professionals assessing transgender and gender diverse adolescents only recommend medical or surgical treatments requested by the patient when all of the following are met:

- The adolescent meets the diagnostic criteria of gender incongruence as per the ICD-11 in situations where a diagnosis is necessary to access health care. In countries that have not implemented the latest ICD, other taxonomies may be used although efforts should be undertaken to utilize the latest ICD as soon as practicable.
- The experience of gender diversity/incongruence is marked and sustained over time.
- The adolescent demonstrates the emotional and cognitive maturity required to provide informed consent/assent for the treatment.
- The adolescent's mental health concerns (if any) that may interfere with diagnostic clarity, capacity to consent, and gender-affirming medical treatments have been addressed.
- The adolescent has been informed of the reproductive effects, including the potential loss of fertility and the available options to preserve fertility, and these have been discussed in the context of the adolescent's stage of pubertal development.
- The adolescent has reached Tanner stage 2 of puberty for pubertal suppression to be initiated.
- The adolescent had at least 12 months of gender-affirming hormone therapy or longer, if required, to achieve the desired surgical result for gender-affirming procedures, including breast augmentation, orchiectomy, vaginoplasty, hysterectomy, phalloplasty, metoidioplasty, and facial surgery as part of gender-affirming treatment unless hormone therapy is either not desired or is medically contraindicated.

In May 2013, the American Psychiatric Association published an update to their Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5). The DSM-5 provided updated diagnostic criteria for gender dysphoria for both children and adults. The new criteria are as follows:<sup>33</sup>

- Gender Dysphoria in Adolescents
  - A marked incongruence between one's experienced/expressed gender and assigned gender, of at least 6 months' duration, as manifested by at least six of the following (one of which must be Criterion A1):
    - A strong desire to be of the other gender or an insistence that one is the other gender (or some alternative gender different from one's assigned gender).
    - In boys (assigned gender), a strong preference for cross-dressing or simulating female attire; or in girls (assigned gender), a strong preference for wearing only typical masculine clothing and a strong resistance to the wearing of typical feminine clothing.

- A strong preference for cross-gender roles in make-believe play or fantasy play.
- A strong preference for the toys, games, or activities stereotypically used or engaged in by the other gender.
- A strong preference for playmates of the other gender.
- In boys (assigned gender), a strong rejection of typically masculine toys, games, and activities and a strong avoidance of rough-and-tumble play; or in girls (assigned gender), a strong rejection of typically feminine toys, games, and activities.
- A strong dislike of one's sexual anatomy.
- A strong desire for the primary and/or secondary sex characteristics that match one's experienced gender.
- The condition is associated with clinically significant distress or impairment in social, school, or other important areas of functioning.

*Specify if:*

- **With a disorder of sex development** [e.g., a congenital adrenogenital disorder such as 255.2 (E25.0) congenital adrenal hyperplasia or 259.50 (E34.50) androgen insensitivity syndrome].
- **Coding note:** Code the disorder of sex development as well as gender dysphoria.
- Gender Dysphoria in Adolescents and Adults
  - A marked incongruence between one's experienced/expressed gender and assigned gender, of at least 6 months' duration, as manifested by at least two of the following:
    - A marked incongruence between one's experienced/expressed gender and primary and/or secondary sex characteristics (or in young adolescents, the anticipated secondary sex characteristics).
    - A strong desire to be rid of one's primary and/or secondary sex characteristics because of a marked incongruence with one's experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics).
    - A strong desire for the primary and/or secondary sex characteristics of the other gender.
    - A strong desire to be of the other gender (or some alternative gender different from one's assigned gender).
    - A strong desire to be treated as the other gender (or some alternative gender different from one's assigned gender).
    - A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one's assigned gender).
  - The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning.

*Specify if:*

- **With a disorder of sex development** [e.g., a congenital adrenogenital disorder such as 255.2 (E25.0) congenital adrenal hyperplasia or 259.50 (E34.50) androgen insensitivity syndrome].
- **Coding note:** Code the disorder of sex development as well as gender dysphoria.

*Specify if:*

- **Post-transition:** The individual has transitioned to full-time living in the desired gender (with or without legalization of gender change) and has undergone (or is preparing to have) at least one cross-sex medical procedure or treatment regimen—namely, regular cross-sex hormone treatment or gender reassignment surgery confirming the desired gender (e.g., penectomy, vaginoplasty in a natal male; mastectomy or phalloplasty in a natal female).

## U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Camcevi™, Eligard®, Firmagon®, Leuprolide Acetate Depot, and Trelstar® are gonadotropin releasing hormone (GnRH) receptor agonists indicated for the palliative treatment of advanced prostate cancer.<sup>27, 29, 41, 43</sup>

Fensolvi®, Lupron Depot-Ped®, Supprelin® LA, and Triptodur are GnRH agonists indicated for the treatment of pediatric patients with central precocious puberty (CPP).<sup>1,28,36</sup>

Lupron Depot® is a GnRH agonist indicated for:<sup>2</sup>

- Management of endometriosis, including pain relief and reduction of endometriotic lesions (3.75 mg for 1-month administration, 11.25 mg for 3-month administration).
- In combination with a norethindrone acetate for initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms (3.75 mg for 1-month administration, 11.25 mg for 3-month administration). Use of norethindrone acetate in combination with Lupron Depot® is referred to as add-back therapy and is intended to reduce the loss of bone mineral density (BMD) and reduce the vasomotor symptoms associated with the use of Lupron Depot®.

- Limitations of Use: Initial treatment course of Lupron Depot® (whether used alone or with add-back therapy) is limited to 6 months. A single retreatment course of not more than 6 months of Lupron Depot® plus add-back therapy may be given if symptoms recur. Do not use Lupron Depot® alone for retreatment. The total duration of therapy with Lupron Depot® 11.25 mg plus add-back therapy should not exceed 12 months due to concerns about adverse impact on bone mineral density.
- Concomitant use with iron therapy for the preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata (fibroids) for whom three months of hormonal suppression is deemed necessary. (3.75 mg for 1-month administration, 11.25 mg for 3-month administration) with recommended duration of therapy up to 3 months.
  - Limitation of use: Lupron Depot® is not indicated for combination use with norethindrone acetate add-back therapy for the preoperative hematologic improvement of women with anemia caused by heavy menstrual bleeding due to fibroids.
- Palliative treatment of advanced prostate cancer (7.5 mg for 1-month administration, 22.5 mg for 3-month administration, 30 mg for 4-month administration, and 45 mg for 6-month administration).\*

Zoladex® is a GnRH agonist indicated for:<sup>30</sup>

- Use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with Zoladex® and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy (10.8 mg and 3.6 mg implant).\*
- Palliative treatment of advanced carcinoma of the prostate (10.8 mg and 3.6 mg implant).\*
- Management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy (3.6 mg implant). Experience with Zoladex® for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months.
- Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding (3.6 mg implant).
- Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women (3.6 mg implant).\*

\*This statement is provided for information only. Oncology indications for GnRH analogs are listed in the NCCN Drugs & Biologics Compendium.

## References

1. Lupron Depot-Ped® [prescribing information]. North Chicago, IL: AbbVie; April 2023.
2. Lupron Depot® [prescribing information]. North Chicago, IL: AbbVie; April 2023.
3. Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Obstet Gynecol. 1999 Jan;93(1):51-8.
4. Dlugi AM, Miller JD, Knittle J. Lupron depot® (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertil Steril. 1990 Sep;54(3):419-27.
5. Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008475.
6. Stovall TG, Muneyirci-Delale O, Summitt RL Jr, Scialli AR. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. Obstet Gynecol. 1995 Jul;86(1):65-71.
7. Friedman AJ, Hoffman DI, Comite F, et al. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol. 1991 May;77(5):720-5.
8. Stovall TG, Ling FW, Henry LC, Woodruff MR. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol. 1991 Jun;164(6 Pt 1):1420-3; discussion 1423-5.
9. Friedman AJ, Harrison-Atlas D, Barbieri RL, et al. A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil Steril. 1989 Feb;51(2):251-6.
10. Management of endometriosis (Reaffirmed 2018). Practice Bulletin 114. American College of Obstetricians and Gynecologists (ACOG). Obstet Gynecol 2010; 116:223-36.
11. Alternatives to hysterectomy in the management of leiomyomas (Reaffirmed 2019). Practice Bulletin 96. American College of Obstetricians and Gynecologists (ACOG). Obstet Gynecol 2008; 112:387-400.
12. MCG™ Care Guidelines, Ambulatory Care, 24<sup>th</sup> Edition. Gonadotropin-Releasing Hormone (GnRH) Agonists.

13. Gold Standard, Inc. Leuprolide. Clinical Pharmacology [database online]. Available at: <https://www.clinicalkey.com/pharmacology/>. Accessed October 9, 2020.
14. Hayes Medical Technology Directory. Hormone Therapy for the Treatment of Gender Dysphoria. May 19, 2014.
15. Brown J, Farquhar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2014 Mar 10;3:CD009590.
16. Chen H, Xiao L, Cui T, Huang W. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2019 Mar 3;(3):CD008018.
17. Lee PA, Klein K, Mauras N, Neely EK, Bloch CA, Larsen L, Mattia-Goldberg C, Chwalisz K. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab. 2012 May;97(5):1572-80.
18. Lee PA, Klein K, Mauras N, Lev-Vaisler T, Bacher P. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. J Clin Endocrinol Metab. 2014 Sep;99(9):3153-9.
19. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines™): Breast Cancer. V4.2023. Available at [www.nccn.org](http://www.nccn.org). Accessed September 11, 2023.
20. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines™): Adolescent and Young Adult (AYA) Oncology. V2.2024. Available at [www.nccn.org](http://www.nccn.org). Accessed September 11, 2023.
21. Song G, Gao H, Yuan Z. Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol. 2013;30(3):667.
22. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K; American Society of Clinical Oncology. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Jul 1;31(19):2500-10.
23. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 2005 Sep;52(9):2761-7.
24. Ben-Aharon I, Gaftor-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2010 Aug;122(3):803-11.
25. Welt CK. Chemotherapy-associated ovaria toxicity. In: UpToDate, Martin KA (Ed), UpToDate, Waltham, MA. Accessed September 11, 2023.
26. Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010 Nov 10;28(32):4831-41.
27. Firmagon® [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals, Inc.; February 2020.
28. Supprelin® LA [prescribing information]. Malvern, PA: Endo Pharmaceuticals Solutions, Inc; April 2022.
29. Trelstar® [prescribing information]. Ewing, NJ: Verity Pharma, Inc.; March 2023.
30. Zoladex® [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2023.
31. Hembree WC, Cohen-Kettenis P, et al. Endocrine Society. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009 Sep;94(9):3132-3154.
32. World Professional Association for Transgender Health. The Harry Benjamin International Gender Dysphoria Association's standards of care for gender identity disorders. Version 7. Minneapolis (MN): WPATH; 2012. Available at: [https://www.wpath.org/media/cms/Documents/SOC%20v7/SOC%20V7\\_English2012.pdf?t=1613669341](https://www.wpath.org/media/cms/Documents/SOC%20v7/SOC%20V7_English2012.pdf?t=1613669341). Accessed April 11, 2016.
33. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. 2013. Washington, DC. Pages 451-459.
34. Costa R, Dunsford M, Skagerberg E, et al. Psychological Support, Puberty Suppression, and Psychosocial Functioning in Adolescents with Gender Dysphoria. J Sex Med 2015; 12:2206-2214.
35. de Vries AL, McGuire JK, Steensma TD, et al. Young adult psychological outcome after puberty suppression and gender reassignment. Pediatrics. 2014 Oct;134(4):696-704.
36. Triptodur [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; April 2022.



37. Hembree WC, Cohen-Kettenis PT, Goorden L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society/Clinical Practice Guideline. J Clin Endocrinol Metab, November 2017, 102(11):1-35.
38. Oktay K, Harvey BE, Partridge AH, et al.; American Society of Clinical Oncology. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018 Jul 1;36(19):1994-2001.
39. Hayes Medical Technology Directory. Hormone Therapy for the Treatment of Gender Dysphoria. April 18, 2017.
40. Fensolvi® [prescribing information]. Fort Collins, CO: Tolmar, Inc.; November 2022.
41. Camcevi™ [prescribing information]. Durham, NC: Accord BioPharma, Inc.; November 2022.
42. Eligard® [prescribing information]. Fort Collins, CO: Tolmar, Inc.; April 2019.
43. Leuprolide Acetate Depot [prescribing information]. Warren, NJ: Cipla USA, Inc.; July 2022.
44. Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228. Obstet Gynecol. 2021 Jun 1;137(6): e100-e115. doi: 10.1097/AOG.0000000000004401. PMID: 34011888.
45. Coleman, E, World Professional Association for Transgender Health (WPATH) Standards of care for the health of transgender and gender diverse people. Version 8. Minneapolis (MN): WPATH; 2022. Available at: [Standards of Care - WPATH World Professional Association for Transgender Health](#). Accessed September 6, 2023.

## Policy History/Revision Information

Date	Summary of Changes
12/01/2024	<b>Template Update</b> <ul style="list-style-type: none"> <li>Modified font style; no change to policy content</li> </ul>
01/01/2024	<b>Template Update</b> <ul style="list-style-type: none"> <li>Created state-specific policy version</li> </ul> <b>Application</b> <ul style="list-style-type: none"> <li>Modified language to indicate this Medical Benefit Drug Policy only applies to the state of Ohio; any requests for services that are stated as unproven or services for which there is a coverage or quantity limit will be evaluated for medical necessity using <i>Ohio Administrative Code 5160-1-01</i></li> </ul> <b>Coverage Rationale</b> <ul style="list-style-type: none"> <li>Revised list of applicable gonadotropin releasing hormone analog (GnRH analog) drug products for non-oncology conditions; added: <ul style="list-style-type: none"> <li>Eligard® (leuprolide acetate)</li> <li>Leuprolide acetate depot</li> </ul> </li> </ul> <b>Applicable Codes</b> <ul style="list-style-type: none"> <li>Added HCPCS code J1954</li> </ul> <b>Supporting Information</b> <ul style="list-style-type: none"> <li>Updated <i>Background</i>, <i>Clinical Evidence</i>, <i>FDA</i>, and <i>References</i> sections to reflect the most current information</li> <li>Archived previous policy version CS2022D0038W</li> </ul>

## Instructions for Use

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state (Ohio Administrative Code [OAC]), or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state (OAC), or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state (OAC), or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state (OAC), or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.